(Q81551024)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Pierre Vandepapelière

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Barbara Rehermann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Marguerite Koutsoukos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Philippe Moris

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Nathalie Garçon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Martine Wettendorff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Geert Leroux-Roels

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

2591-2601

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

T cell mediated immunity to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Prospects for vaccines to protect against AIDS, tuberculosis, and malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

DNA vaccines: a key for inducing long-term cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

DNA vaccination for HIV-1 and SIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Recent developments in adjuvants for vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

The development and use of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

QS-21: a water-soluble triterpene glycoside adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Adjuvants--a balance between toxicity and adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

Properties of a recombinant yeast-derived hepatitis B surface antigen containing S, preS2 and preSl antigenic domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of a nontoxic monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.034

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.11.034

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15780441%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference